





Adanma Ayanambakkam¹, Anh Lam¹, Kieran Sweeney², Andrew Elliott², Chadi Nabhan², Rana R. Mckay³, Abhishek Tripathi⁴, Sumati Gupta⁵, Xu Chao¹, Jad Chahoud⁶, Debasish Sundi⁷, Paul Skelton⁸, Laura Graham⁹, Lyudmyla Berim¹⁰, Bodour Salhia¹¹, Sean Kern¹², Yousef Zakharia¹³, Stephen Edge¹⁴, Abdul Rafeh Naqash¹

¹Stephenson Cancer Center, OK; ²Caris Life Sciences; ³University of California San Diego, CA; ⁴City of Hope Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Cancer Center, FL; ⁶Ohio State University, OH; ⁸UVA Health Emily Couric Cancer Center; ¹Stephenson Center; ¹Stephe ⁹University of Colorado Cancer Center; ¹⁰Rutgers Cancer Institute of New Jersey, NJ; ¹¹USC Norris Cancer Center, ¹²Murtha Cancer Center, MD; ¹³Holden Cancer Center, IA; ¹⁴Roswell Park Cancer Center, NY

INTRODUCTION

- LAG3 is an immune checkpoint receptor protein expressed on immune cells, and LAG3 negatively regulates T-cell function and can promote tumor cell immune escape
- Co-blockade of PD1 and LAG3 enhanced anti-tumor responses in preclinical mouse models (ovarian cancer and colon adenocarcinoma)
- Nivolumab (anti-PD1) and Relatlimab (anti-LAG3) combination therapy has been approved to treat metastatic melanoma
- Despite its established prognostic significance in other malignancies, the role of *LAG3* as a prognostic or predictive biomarker in urothelial carcinoma (UC) remains inadequately studied

METHODS

- DNA (592-gene or whole exome) and RNA (whole transcriptome) sequencing were performed for 3343 patient tumors submitted to *Caris Life Sciences*
- Clinical and molecular data from patients enrolled in the <u>Oncology Research</u> Information Exchange Network (ORIEN), including tumor RNA-seq sequencing, were used as a validation cohort for analysis
- In this study, we investigate the correlation between LAG3 expression levels in tumor tissues of patients diagnosed with urothelial carcinoma and a range of clinicopathological parameters. We also assessed the impact on overall survival and response to standard therapies, aiming to elucidate potential mechanisms of resistance.
- PD-L1+ status (22c3, combined positive score \geq 10) was determined by IHC and TMB-High (TMB-H) was defined as ≥ 10 mutations/Mb
- LAG3 high (LAG3-H) and low (LAG3-L) cohorts were defined by the top and bottom quartiles of LAG3 RNA transcripts per million (TPM), respectively
- Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTlseq
- Significance was tested using Mann-Whitney U and χ^2 tests with multiple testing correction as appropriate
- Real-world overall survival (OS) was obtained from insurance claims data and calculated from start of Atezolumab, Avelumab, Nivolumab or Pembrolizumab to last contact.
- Pembrolizumab time on treatment (ToT) was calculated from start of Pembrolizumab to last of Pembrolizumab
- Hazard ratios (HR) and associated p-values were calculated using the Cox proportional hazards model
- Multivariate analysis (MVA) was performed using a Cox Proportional-Hazards model

MULTI-OMIC ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF LAG3 EXPRESSION IN UROTHELIAL CARCINOMA




Figure 1. LAG3 expression in UC and association with increased TP53 mutations and PD-L1+ and TMB-H status

- (Top left) *LAG3* expression in UC vs metastatic melanoma patients treated with Nivolumab + Relatlimab combination therapy
- (Bottom left) Demographics of LAG3-H and LAG3-L cohorts
- (Right) Prevalence of genetic alterations vs *LAG3* expression quartile. Qvalues for LAG3-H vs LAG3-L comparisons




Figure 2. LAG3-H cohort had increased immune cell infiltration and increased Tregs

- (Left) Immune cell fractions vs LAG3 expression quartile
- (Right) Total immune cell fractions by *LAG3* expression quartile. Stars represent q-values for LAG3-H vs LAG3-L comparisons

RESULTS




Figure 3. High LAG3 expression associated with longer OS and **Pembrolizumab ToT**

- (Left) Post-ICI OS for LAG3-H vs LAG3-L cohorts
- (Right) *LAG3* expression in cohorts stratified by Pembrolizumab ToT




Figure 4. Longer OS for LAG3-H cohort persisted in PD-L1+ and TMB-H tumors

- Post-ICI OS for LAG3-H vs LAG3-L cohorts among PD-L1 IHC+ tumors (top left) and TMB-H tumors (bottom left)
- (Right) HRs and 95% CI from Multivariate analysis







VALIDATION COHORT




Figure 5. Validation cohort utilizing the ORIEN database

- (Left) OS for LAG3-H vs LAG3-L cohorts in ORIEN database
- (Right) LAG3 expression vs prevalence of FGFR3 mutations (spearman correlation coefficient = -0.205, p<0.0001)

CONCLUSIONS

- In UC, high LAG3 expression is associated with improved survival and a hot tumor micro-environment
- Among patients with TMB-H, who received immune checkpoint inhibitors (ICI), LAG3-H had improved OS vs LAG3-L (HR=0.69, p=0.039).
- High LAG3 is associated with increased TP53 and RB1 mutations, decreased FGFR3 mutations, and increased PD-L1 IHC+ and TMB-H status
- UC patients may benefit from combination ICI because high LAG3 expression is associated with increased immune cell infiltration, but also higher levels of inhibitory Tregs



Adanma Ayanambakkam, MD

adanma-Ayanambakkam@ouhsc.edu 800 NE 10th street, Oklahoma City, OK 73104 Stephenson Cancer Center, University of Oklahoma